{"entity":{"id":"nct02340117","kind":"trial","name":"Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer","aka":[],"tldr":"A phase 2 trial of Gemcitabine in pancreatic ductal adenocarcinoma, run by SynerGene Therapeutics, Inc., active and no longer recruiting.","summary":"Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer is a phase 2 interventional study registered as NCT02340117 by SynerGene Therapeutics, Inc., with 28 participants enrolled, started 2015-01 and due to reach its primary completion in 2026-12. Interventions recorded: SGT-53, nab-paclitaxel and Gemcitabine.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT02340117","url":"https://clinicaltrials.gov/study/NCT02340117"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":["gemcitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT02340117","phase":"2","setting":"Phase II Study of Combined Targeted p53 Gene Therapy (SGT-53) Plus Gemcitabine/Nab-Paclitaxel for Treatment of Metastatic Pancreatic Cancer","sponsor":"SynerGene Therapeutics, Inc.","enrolled":28,"outcomes":[]},"route":"/trials/nct02340117/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"drug":[{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"}]}}